bluuebunny/crossref_metadata_2025_split huggingface dataset:
Approaches to neuropathic amputation-related pain: narrative review of surgical, interventional, and medical treatments
Authors: Markewych Adrian N , Suvar Tolga , Swanson Marco A , Graca Mateusz J , Lubenow Timothy R , McCarthy Robert J , Buvanendran Asokumar , Kurlander David E 
Published: February 2024

Background/importanceNeuropathic amputation-related pain can consist of phantom limb pain (PLP), residual limb pain (RLP), or a combination of both pathologies. Estimated of lifetime prevalence of pain and after amputation ranges between 8% and 72%.ObjectiveThis narrative review aims to summarize the surgical and non-surgical treatment options for amputation-related neuropathic pain to aid in developing optimized multidisciplinary and multimodal treatment plans that leverage multidisciplinary care.Evidence reviewA search of the English literature using the following keywords was performed: PLP, amputation pain, RLP. Abstract and full-text articles were evaluated for surgical treatments, medical management, regional anesthesia, peripheral block, neuromodulation, spinal cord stimulation, dorsal root ganglia, and peripheral nerve stimulation.FindingsThe evidence supporting most if not all interventions for PLP are inconclusive and lack high certainty. Targeted muscle reinnervation and regional peripheral nerve interface are the leading surgical treatment options for reducing neuroma formation and reducing PLP. Non-surgical options include pharmaceutical therapy, regional interventional techniques and behavioral therapies that can benefit certain patients. There is a growing evidence that neuromodulation at the spinal cord or the dorsal root ganglia and/or peripheral nerves can be an adjuvant therapy for PLP.ConclusionsMultimodal approaches combining pharmacotherapy, surgery and invasive neuromodulation procedures would appear to be the most promising strategy for preventive and treating PLP and RLP. Future efforts should focus on cross-disciplinary education to increase awareness of treatment options exploring best practices for preventing pain at the time of amputation and enhancing treatment of chronic postamputation pain.
THE JARROW AND TURNBULL SETTING REVISITED
Authors: KRABICHLER THOMAS , TEICHMANN JOSEF 
Published: February 2024

We consider a financial market with zero-coupon bonds that are exposed to credit and liquidity risk. We revisit the famous Jarrow & Turnbull ( 1995 ) setting in order to account for these two intricately intertwined risk types. We utilize the foreign exchange analogy that interprets defaultable zero-coupon bonds as a conversion of nondefaultable foreign counterparts. The relevant exchange rate is only partially observable in the market filtration, which leads us naturally to an application of the concept of platonic financial markets as introduced by Cuchiero et al. ( 2020 ). We provide an example of tractable term structure models that are driven by a two-dimensional affine jump diffusion. Furthermore, we derive explicit valuation formulae for marketable products, e.g. for credit default swaps.
Prospective Analysis of Simulated Pneumatic Tourniquet Use and Oedema Following Axillary Lymph Node Dissection
Authors: WU Edward J. , LAI Cara H. , MURAOKA Kunihide , SEGOVIA Nicole , KLEIMEYER John P. , YAO Jeffrey 
Published: February 2024

Background: Tourniquet use during upper extremity surgery in patients with a history of axillary lymph node dissection (ALND) remains controversial due to the perceived but unproven risk of lymphoedema. We prospectively evaluated upper extremity swelling in patients with a history of unilateral ALND using a standardised tourniquet model. Methods: A tourniquet was applied to the upper arm bilaterally, with the unaffected side serving as an internal control. Each arm was subsequently held in an elevated position to reduce swelling. Hand volume was measured using an aqueous volumeter. Results: The patients’ ALND arms experienced slightly greater increases in volume following tourniquet application compared to their healthy control arms. However, this amount of oedema was temporary and reversible, as both arms experienced spontaneous resolution of swelling with no significant difference in residual hand volume at the conclusion of the study. Conclusions: Tourniquet use may be safe in patients with a history of ALND. Further investigation is needed to verify this in a surgical setting. Level of Evidence: Level II (Therapeutic)
Reconstruction of the Cretaceous continental arc–trench system of the Japanese Islands: a basis for Cretaceous palaeoenvironmental studies
Authors: Ando Hisao , Takahashi Masaki 
Published: February 2024

Abstract
Spatiotemporal distributions of Cretaceous rocks differ markedly between the SW and NE Japan arcs. However, four parallel zonal arrangements of rocks are recognized broadly throughout both arcs: mostly non-marine sedimentary rocks in back-arc/intra-arc basins; granitic and volcanic rocks in magmatic arcs; predominantly marine and subordinately fluvial sedimentary rocks in forearc basins; and sedimentary rocks of turbiditic and mélange facies in accretionary complexes. These zones constituted a palaeo-Japan continental arc–trench system during the Cretaceous. We describe and correlate 71 Cretaceous back-arc/intra-arc and forearc basinal successions from Kyushu (south) to Hokkaido (north) islands, including a southern Sakhalin and two Kuril Arc (eastern Hokkaido) successions.
Stratigraphic ranges and major sedimentary facies are generally similar between the SW and NE Japan arcs, except for the pre-Aptian Lower Cretaceous in Hokkaido of NE Japan, suggesting continuity throughout the two arcs during the Cretaceous. Although Cretaceous strata are sporadically exposed in northern Honshu, NE Japan, interpretation of seismic sections suggests that Cretaceous forearc sedimentary rock measuring several tens of kilometres laterally are developed offshore beneath the present Pacific forearc. In contrast, Cretaceous forearc strata in southern SW Japan are distributed along two narrow belts that may have been deformed by post-Early Miocene tectonism.
Abstract A023: lncRNA-protein interactions that predict response to endocrine therapy in HR+ breast cancer
Authors: Waiters Kacie D , Quttina Maram , Khan Ashfia F , Karami Samaneh , Peidl Anthony , Babajide Funmi , Bawa-Khalfe Tasneem 
Published: February 2024

Abstract
Hormone receptor positive (HR+) breast cancer (BCa) is the most frequently diagnosed BCa type accounting for 70% of all breast cancer cases. A large population of HR+ BCa patients (30-40%) are resistant to mainstay endocrine therapy and develop incurable metastatic disease. Hence, it is imperative to identify viable biomarkers that stratify patients as drug responders or non-responders. Emerging scientific literature highlights the essential role of long non-coding RNAs (lncRNA), a class of RNAs over 200 nucleotides in length that do not encode protein, in cancer drug resistance and metastatic transformation. Major biological functions of lncRNA rely on association with select protein interactors. As lncRNA equally bind proteins with and without canonical RNA-binding motifs, it is unclear what facilitates this lncRNA-protein interaction. Our recent studies show that SUMO post-translational modification (or SUMOylation) of target proteins potentiates binding with lncRNA, particularly at the chromatin. SUMOylation of heterochromatin protein 1 α (HP1α) drives interaction with multiple chromatin-associated lncRNA both within and outside canonical heterochromatin foci. Interaction with lncRNA supports SUMOylated HP1α’s unconventional function as a transcriptional repressor at select euchromatic loci. We now report an inverse relationship in which SUMOylated HP1α directs the stability of its lncRNA binding partner. Specifically, SUMO-modified HP1α directs cell-cycle dependent recruitment of the RNA degradation machinery to the chromatin and facilitates clearance of chromatin-bound lncRNA. This dynamic lncRNA degradation process is disturbed with cancer onset and instead favors aberrant cancer cell transformation. Consistently, restoring lncRNA degradation homeostasis decreases metastatic properties of HR+ BCa cells and increases sensitivity to targeted therapeutics currently in clinical trials. Our studies define a fundamental mechanism that dictates lncRNA stability and/or degradation in BCa cells. In addition, we present viable biomarkers that predict sensitivity to ET and alternative targeted therapies.
Citation Format: Kacie D Waiters, Maram Quttina, Ashfia F Khan, Samaneh Karami, Anthony Peidl, Funmi Babajide, Tasneem Bawa-Khalfe. lncRNA-protein interactions that predict response to endocrine therapy in HR+ breast cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Breast Cancer Research; 2023 Oct 19-22; San Diego, California. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_1):Abstract nr A023.
Abstract A031: The role of nuclear epidermal growth factor receptor in cell migration and wound healing
Authors: DiFranco Danielle M , Schroeder Joyce 
Published: February 2024

Abstract
In breast cancer cells, epidermal growth factor receptor (EGFR) can retrotranslocate to the nucleus where it acts as a transcription cofactor and activates pro-oncogenic pathways such as stemness and migration. This retrotranslocation can occur through interaction with the BAR domain-containing protein Sorting Nexin 1 (SNX1). Upon retrotranslocation, EGFR is removed from the membrane via the Sec61 translocon, where the now soluble EGFR can interact with heat shock proteins and nuclear importins via its conserved nuclear localization sequence (NLS). Presence of the NLS in all wildtype EGFR indicates nuclear EGFR (nEGFR) also plays a role in non-cancerous tissue. EGFR is a known contributor to wound-healing, migration, and mammary gland development but the role of nEGFR in these processes has yet to be elucidated. Our lab has created cSNX1.3, a peptide-based therapeutic that recapitulates the BAR domain of Sorting Nexin 1. CSNX1.3 competitively binds to EGFR to prevent nuclear trafficking, and this treatment is effective at killing cancer cells that express EGFR, while leaving non-cancerous cells alive. In addition, cSNX1.3 is a potent inhibitor of EGF-dependent cell migration in Triple Negative Breast Cancer cell lines. Based on this data, we hypothesize that, in response to a wound, nEGFR activates cell migration pathways to promote wound healing. To better understand the role of nEGFR in wound healing and migration of non-cancer cell types, we have utilized CRISPR/Cas9 to insert mScarlet or mVenus, improved fluorescent proteins, onto the C-terminus of endogenous EGFR in immortalized MCF10A cells. Using a live cell imaging platform, we discovered that cells on the leading edge of a wound have increased levels of nEGFR. Furthermore, treatment with cSNX1.3 inhibits the migration of MCF10As and reduces levels of nEGFR. This data implies a role for nEGFR in the migration of MCF10As during wound healing. Future studies will delve deeper into the triggers of EGFR retrotranslocation to the nucleus and investigate the specific proteins nEGFR interacts with to affect cell migration. By elucidating the intrinsic role of nuclear EGFR in non-cancerous tissue types, we can better understand how cancer takes advantage of these molecular pathways and possibly its role in the cell migration essential to metastatic progression.
Citation Format: Danielle M DiFranco, Joyce Schroeder. The role of nuclear epidermal growth factor receptor in cell migration and wound healing [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Breast Cancer Research; 2023 Oct 19-22; San Diego, California. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_1):Abstract nr A031.
Abstract B003: Investigating PHLDA2 as a Genetic Driver of Breast Cancer Metastasis
Authors: Halas Paige , Savage Hannah , Ma Dennis , Insua-Rodriguez Jacob , Mallya Sharmila , Chan Connie , Domadia Radhika , Lev Tatyana , Lawson Devon 
Published: February 2024

Abstract
Metastasis is cancer’s lethal driver. Metastatic cancer cells leave the primary tumor and travel through the blood stream to distal sites. These cancer cells are aggressive, highly recurring and pose challenges for clinical treatment. There is a critical need to define drivers of metastasis in order to identify novel drug targets and improve patient prognosis. Our previous work identified a potential breast cancer metastasis promoting gene known as PHLDA2. By single cell RNA sequencing, PHLDA2 gene expression was elevated in metastatic lesions compared to primary breast tumor tissue. This gene has not previously been linked to cancer metastasis; therefore, the objective of the current study is to confirm PHLDA2 as a driver of breast cancer metastasis and define the mechanisms by which it exerts its pro-metastatic function. We manipulated multiple breast cancer models to have elevated or reduced PHLDA2 levels to investigate its role in metastasis. We have additionally explored the mechanism of PHLDA2 in metastasis at the RNA level by qPCR, the protein level by western blot analysis, and the organ level using immunofluorescence staining and bulk sequencing. We confirmed using our breast cancer models of elevated or reduced PHLDA2 expression that PHLDA2 has a pro-metastatic function. Bulk RNA sequencing data revealed that PHLDA2 promotes extracellular matrix (ECM) remodeling. This finding is significant as ECM remodeling plays a critical role in cancer progression and metastasis. Investigation of PHLDA2’s pro-metastatic function is necessary to gain deeper insights into the mechanisms of cancer cell spread and reveal novel drug targets to improve patient survival.
Citation Format: Paige Halas, Hannah Savage, Dennis Ma, Jacob Insua-Rodriguez, Sharmila Mallya, Connie Chan, Radhika Domadia, Tatyana Lev, Devon Lawson. Investigating PHLDA2 as a Genetic Driver of Breast Cancer Metastasis [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Breast Cancer Research; 2023 Oct 19-22; San Diego, California. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_1):Abstract nr B003.
Abstract A020: An early determination of patients eligibility for a bladder cancer immunotherapy using a data science approach
Authors: Olumoyin Kayode D. , Aydin Ahmet M. , Bunch Brittany L , Pilon-Thomas Shari , Poch Michael , Rejniak Katarzyna A. 
Published: February 2024

Abstract
Advanced bladder cancer patients have limited treatment options and, in most cases, limited overall survival. The first clinical trial with adoptive T cell therapy (ACT) that uses bladder cancer patients’ autologous tumor-infiltrating T lymphocytes (TILs) has been recently opened at Moffitt. To help identify which patients could benefit from ACT-TIL we are developing a machine learning predictor that takes advantage of tumor evolution data, such as tumor stages and grades routinely collected in clinic. The first phase of ACT-TIL involves resection of the primary tumor and the growth of TILs followed by a rapid expansion protocol of the reactive T cells. It may take up to 4-5 weeks before bladder cancer patients can get their own expanded TILs. Our predictor aims to determine whether the tumor isolated from a patient will grow TILs. In this work, we present a machine learning predictor of expansion of tumor infiltrating lymphocytes (ML-PETIL) that uses retrospectively collected patient tumor data with either demographic, clinical, or biological sample-related features. The proposed method consists of a suite of algorithms to identify a robust set of predictive features (feature selection algorithms) that are used to discriminate the dataset into two classes-that with successful TIL expansion or with no TIL growth (classification algorithms). Our predictor includes metrics which are used to address data imbalance and handle small to medium-sized datasets that contain features of varying datatypes and magnitudes. The ML-PETIL protocol offers an early determination of patients who would be eligible for ACT-TIL therapy.
Citation Format: Kayode D. Olumoyin, Ahmet M. Aydin, Brittany L Bunch, Shari Pilon-Thomas, Michael Poch, Katarzyna A. Rejniak. An early determination of patients eligibility for a bladder cancer immunotherapy using a data science approach [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Translating Cancer Evolution and Data Science: The Next Frontier; 2023 Dec 3-6; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_2):Abstract nr A020.
Supplementary Figure 7 from Immune Modulation of Innate and Adaptive Responses Restores Immune Surveillance and Establishes Antitumor Immunologic Memory
Authors: Alvero Ayesha B. , Fox Alexandra , Madina Bhaskara Reddy , Krady Marie M. , Gogoi Radhika , Chehade Hussein , Nakaar Valerian , Almassian Bijan , Yarovinsky Timur O. , Rutherford Thomas , Mor Gil 
Published: February 2024

<p>A. Mean tumor burden over time of nude mice bearing OCSC1-F2 human ovarian tumors. mCherry fluorescent ROI was used to provide a measure of tumor burden. Data are presented as mean ± SEM. Treatments began on day 6 and continued through to day 12.
B. Survival analysis using Kaplan-Meier.
</p>
Benchmarking Large Language Models for News Summarization
Authors: Zhang Tianyi , Ladhak Faisal , Durmus Esin , Liang Percy , McKeown Kathleen , Hashimoto Tatsunori B. 
Published: February 2024

Abstract
Large language models (LLMs) have shown promise for automatic summarization but the reasons behind their successes are poorly understood. By conducting a human evaluation on ten LLMs across different pretraining methods, prompts, and model scales, we make two important observations. First, we find instruction tuning, not model size, is the key to the LLM’s zero-shot summarization capability. Second, existing studies have been limited by low-quality references, leading to underestimates of human performance and lower few-shot and finetuning performance. To better evaluate LLMs, we perform human evaluation over high-quality summaries we collect from freelance writers. Despite major stylistic differences such as the amount of paraphrasing, we find that LLM summaries are judged to be on par with human written summaries.
Differential Treatment and Temporary Protection Arrangements: Discrimination or Legitimate Distinctions?
Authors: Kienast Julia , Vedsted-Hansen Jens 
Published: February 2024

Abstract
This article analyses the differential treatment among refugees inherent to temporary protection arrangements. What was particularly remarkable in the EU’s response to displacement from Ukraine, for instance, was the free access for Ukrainians to EU territory and even free choice to seek protection in any Member State. Thus, the persons under this arrangement are better off initially, and this may seem preferable to the deterrence measures taken in response to other cases of ‘mass influx’ which restricted, rather than facilitated, access to protection. As it may in the longer term be better for some refugees to undergo the ordinary asylum procedure and eventually receive refugee or subsidiary protection status, temporary protection raises complex questions of differential treatment. At the same time, within the ordinary asylum procedure some EU Member States have introduced distinctions resulting in differential treatment of certain refugee categories whose need for protection is perceived to be temporary. This article positions the implementation of the various temporary protection arrangements within the general norms of non-discrimination by analysing key aspects of differential treatment and attempting to identify the boundary between lawful and unlawful distinctions.
The More Favourable Provision Clause in EU Migration Law: Expanding Fundamental Rights through National Discretion?
Authors: Romano Andrea 
Published: February 2024

Abstract
Interaction between different levels of fundamental rights protection is a widely debated topic in EU scholarship, which has long dealt with situations in which national legislation lowered legal standards in the EU. Less explored, however, is the opposite case: when Member State regulations set standards higher than those enshrined at EU level. This can occur through application of the more favourable provision (MFP) clause – commonly enshrined in EU directives dealing with (but not limited to) immigration and asylum. Under it, Member States can apply more favourable standards insofar as they comply with EU legislation. Though seldom discussed in existing literature, the MFP clause is a critical issue of EU migration law and illustrative of challenges facing the EU constitutional order, for it highlights the relationship between fundamental rights protection in the multi-layered EU system and general principles of EU law. Against this backdrop, this paper will investigate the features of the MFP clause in EU migration law and analyse the CJEU’s adjudication in immigration and asylum cases, exploring its reasoning in testing application of MFP clause against EU law.
Mechanical properties of a carbon fiber reinforced epoxy resin composite improved by integrating multi-walled carbon nanotubes and graphene nanoplatelets
Authors: Yuksel Esranur , Eksik Osman , Haykiri-Acma Hanzade , Yaman Serdar 
Published: February 2024

The pairs of nanofillers prepared by graphene nanoplatelets (GNPs) and multi-walled carbon nanotubes (MWCNTs) were added to the epoxy matrix in various ratios to produce hybrid epoxy nanocomposites. The effects of the presence of these nanofillers at 0.1–0.4 wt.% on the mechanical and thermal properties were tested. Likewise, carbon fiber reinforced MWCNT/GNP modified epoxy nanocomposite laminates were also manufactured and tested. The dispersion of nanofiller in the polymer matrix was evaluated by Scanning Electron Microscopy (SEM). It was determined that the hybrid composite consisting of a MWCNT:GNP ratio of 1:3 and a nanofiller ratio of 0.3 wt.% showed the best mechanical properties with a tensile strength of 75.1 MPa. The presence of GNPs and MWCNT nanofillers in epoxy/carbon fiber laminates influenced positively the tensile strength and strain but negatively the elastic modulus. Glass transition temperature of epoxy increased from 87.25°C to 114.67°C for MWCNT:GNP ratio of 1:1 (0.3 wt.%).